CY1122231T1 - Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη - Google Patents
Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατηInfo
- Publication number
- CY1122231T1 CY1122231T1 CY20191100752T CY191100752T CY1122231T1 CY 1122231 T1 CY1122231 T1 CY 1122231T1 CY 20191100752 T CY20191100752 T CY 20191100752T CY 191100752 T CY191100752 T CY 191100752T CY 1122231 T1 CY1122231 T1 CY 1122231T1
- Authority
- CY
- Cyprus
- Prior art keywords
- imidazolidin
- thioxo
- ones
- substituted
- treatment
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical class O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 abstract 1
- 229940123407 Androgen receptor antagonist Drugs 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000003936 androgen receptor antagonist Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η εφεύρεση αφορά νέα (R)-στερεοϊσομερή υποκατεστημένων 2-θειοξο-ιμιδαζολιδιν-4-ονών του τύπου 1, ή σπειρο ανάλογα αυτών, τα οποία εμφανίζουν ιδιότητες ανταγωνιστή υποδοχέα ανδρογόνων, παραλλαγές μιας μεθόδου για παραγωγή αυτών και ενδιάμεσες ενώσεις για παραγωγή ενώσεων του τύπου 1. Οι ενώσεις του τύπου 1 μπορούν να χρησιμοποιηθούν για την παραγωγή ενός φαρμακευτικού παράγοντα, κατάλληλου για τη θεραπεία καρκίνων, όπως ο καρκίνος του προστάτη και ο καρκίνος του μαστού. Η εφεύρεση αφορά επίσης μια φαρμακευτική σύνθεση σε μορφή δισκίων, κάψουλων και ενέσεων. Στο τύπο 1, R1 είναι ΟΗ, ΝΗ2 ή μια OR4 ομάδα· R2 και R3 είναι μεθύλιο, ή R2 και R3 είναι μια CH2-CH2 ομάδα· R4 είναι C1-C4 αλκύλιο ή κυκλοπροπύλιο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014127705/04A RU2557235C1 (ru) | 2014-07-08 | 2014-07-08 | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
PCT/RU2015/000395 WO2016007046A1 (ru) | 2014-07-08 | 2015-06-26 | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122231T1 true CY1122231T1 (el) | 2020-11-25 |
Family
ID=53611746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100752T CY1122231T1 (el) | 2014-07-08 | 2019-07-15 | Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη |
Country Status (22)
Country | Link |
---|---|
US (1) | US10450278B2 (el) |
EP (1) | EP3168214B1 (el) |
JP (1) | JP6581193B2 (el) |
KR (1) | KR102171120B1 (el) |
AU (1) | AU2015288381B2 (el) |
CA (1) | CA2954401C (el) |
CY (1) | CY1122231T1 (el) |
DK (1) | DK3168214T3 (el) |
ES (1) | ES2736507T3 (el) |
GE (1) | GEP20207096B (el) |
HR (1) | HRP20191265T8 (el) |
HU (1) | HUE044317T2 (el) |
LT (1) | LT3168214T (el) |
PL (1) | PL3168214T3 (el) |
PT (1) | PT3168214T (el) |
RS (1) | RS59009B1 (el) |
RU (1) | RU2557235C1 (el) |
SI (1) | SI3168214T1 (el) |
TR (1) | TR201910220T4 (el) |
UA (1) | UA117626C2 (el) |
WO (1) | WO2016007046A1 (el) |
ZA (1) | ZA201700922B (el) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3030181A1 (en) * | 2016-07-08 | 2018-01-11 | Janssen Pharmaceutica Nv | Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists |
CN107954936B (zh) * | 2016-10-17 | 2021-03-19 | 海创药业股份有限公司 | 一种制备氘代咪唑二酮类化合物的方法 |
CN109422725A (zh) * | 2017-09-04 | 2019-03-05 | 北京美倍他药物研究有限公司 | 前列腺癌治疗药物 |
RU2708253C2 (ru) * | 2017-12-05 | 2019-12-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Новые производные арил-тиогидантоина, ингибиторы андрогенового рецептора, способ получения и применения |
EP3897636A4 (en) * | 2018-12-19 | 2022-09-07 | Celgene Corporation | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATING THEREOF |
BR112021012186A2 (pt) * | 2018-12-19 | 2021-08-31 | Celgene Corporation | Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos |
CN114621109B (zh) * | 2020-12-14 | 2024-04-26 | 成都苑东生物制药股份有限公司 | 一种阿帕他胺的合成方法及其中间体 |
CN113698310B (zh) * | 2021-08-20 | 2023-03-17 | 江西金丰药业有限公司 | 一种恩杂鲁胺双酯中间体的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006248109B2 (en) * | 2005-05-13 | 2012-11-15 | The Regents Of The University Of California | Diarylhydantoin compounds |
MX2011008858A (es) * | 2009-02-24 | 2012-01-27 | Medivation Prostate Therapeutics Inc | Compuestos de diarilhidantoina y diariltiohidantoina especificos. |
EP3124481B1 (en) * | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
JP5718372B2 (ja) * | 2010-02-24 | 2015-05-13 | メディベイション プロステイト セラピューティクス, インコーポレイテッド | ジアリールチオヒダントイン化合物およびジアリールヒダントイン化合物を合成するためのプロセス |
RU2434851C1 (ru) * | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения |
RU2520134C1 (ru) * | 2013-02-27 | 2014-06-20 | Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") | Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения |
-
2014
- 2014-07-08 RU RU2014127705/04A patent/RU2557235C1/ru active
-
2015
- 2015-06-26 PL PL15818878T patent/PL3168214T3/pl unknown
- 2015-06-26 JP JP2017522315A patent/JP6581193B2/ja active Active
- 2015-06-26 UA UAA201700635A patent/UA117626C2/uk unknown
- 2015-06-26 DK DK15818878.9T patent/DK3168214T3/da active
- 2015-06-26 AU AU2015288381A patent/AU2015288381B2/en active Active
- 2015-06-26 RS RS20190891A patent/RS59009B1/sr unknown
- 2015-06-26 HU HUE15818878 patent/HUE044317T2/hu unknown
- 2015-06-26 PT PT15818878T patent/PT3168214T/pt unknown
- 2015-06-26 SI SI201530801T patent/SI3168214T1/sl unknown
- 2015-06-26 WO PCT/RU2015/000395 patent/WO2016007046A1/ru active Application Filing
- 2015-06-26 GE GEAP201514411A patent/GEP20207096B/en unknown
- 2015-06-26 EP EP15818878.9A patent/EP3168214B1/en active Active
- 2015-06-26 US US15/324,658 patent/US10450278B2/en active Active
- 2015-06-26 CA CA2954401A patent/CA2954401C/en not_active Expired - Fee Related
- 2015-06-26 KR KR1020177003384A patent/KR102171120B1/ko active IP Right Grant
- 2015-06-26 ES ES15818878T patent/ES2736507T3/es active Active
- 2015-06-26 LT LTEP15818878.9T patent/LT3168214T/lt unknown
- 2015-06-26 TR TR2019/10220T patent/TR201910220T4/tr unknown
-
2017
- 2017-02-06 ZA ZA2017/00922A patent/ZA201700922B/en unknown
-
2019
- 2019-07-15 CY CY20191100752T patent/CY1122231T1/el unknown
- 2019-07-16 HR HRP20191265T patent/HRP20191265T8/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP3168214A4 (en) | 2018-02-14 |
EP3168214B1 (en) | 2019-04-24 |
EP3168214A1 (en) | 2017-05-17 |
HRP20191265T1 (hr) | 2019-10-18 |
AU2015288381B2 (en) | 2019-11-07 |
AU2015288381A1 (en) | 2017-03-02 |
PT3168214T (pt) | 2019-07-25 |
DK3168214T3 (da) | 2019-07-22 |
JP2017522379A (ja) | 2017-08-10 |
ZA201700922B (en) | 2019-08-28 |
GEP20207096B (en) | 2020-04-10 |
US20180179164A1 (en) | 2018-06-28 |
RU2557235C1 (ru) | 2015-07-20 |
SI3168214T1 (sl) | 2019-09-30 |
KR102171120B1 (ko) | 2020-10-29 |
WO2016007046A1 (ru) | 2016-01-14 |
CA2954401A1 (en) | 2016-01-14 |
UA117626C2 (uk) | 2018-08-27 |
HUE044317T2 (hu) | 2019-10-28 |
JP6581193B2 (ja) | 2019-09-25 |
TR201910220T4 (tr) | 2019-07-22 |
HRP20191265T8 (hr) | 2019-11-01 |
US10450278B2 (en) | 2019-10-22 |
CA2954401C (en) | 2021-03-02 |
ES2736507T3 (es) | 2020-01-02 |
PL3168214T3 (pl) | 2019-10-31 |
LT3168214T (lt) | 2019-07-25 |
RS59009B1 (sr) | 2019-08-30 |
KR20170023184A (ko) | 2017-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122231T1 (el) | Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη | |
CY1123649T1 (el) | Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη | |
PH12018500591A1 (en) | Heterocyclic compounds and uses thereof | |
ECSP18090144A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
PH12015501996B1 (en) | Heterocyclic compounds and uses thereof | |
CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
NZ721617A (en) | Heterocyclic compounds | |
NI201400150A (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
CR20140399A (es) | Pirrolidina-2-carboxamidas sustituidas | |
CO2017008600A2 (es) | Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos | |
DOP2017000034A (es) | Compuestos de imidazopiridazina | |
CY1120680T1 (el) | Ανταγωνιστες η3 που περιεχουν συνταξη πυρηνα φαινοξυπιπεριδινης | |
ECSP17069696A (es) | Compuestos novedosos | |
CO2020007222A2 (es) | Proceso para la preparación de derivados antihelmínticos de 4-amino-quinolin-3-carboxamida | |
CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
PH12016500322A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
TR201819805T4 (tr) | Flavaglin türevleri̇. | |
CY1122172T1 (el) | Τροποποιητες θειαζολης των a3 υποδοχεων αδενοσινης | |
CR20160373A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
MX363334B (es) | Una forma cristalina anhidra de cabazitaxel, procedimiento para la preparación y composiciones farmacéuticas del mismo. | |
PH12018500014A1 (en) | Total synthesis of shishijimicin a and analogs thereof |